Crohn's & Colitis
Crohn’s disease and ulcerative colitis (UC), both also known as inflammatory bowel diseases (IBD), are autoimmune diseases in which the body’s immune system attacks the intestines, resulting in intestinal inflammation, abdominal pain and bleeding.
BRI's immunology research into IBD focuses on understanding the processes that initiate and perpetuate the inflammation, on designing targeted immune therapies to block or reverse these processes, and on clinical trials to evaluate effectiveness and safety of immune modulation in patients with ongoing disease.
BRI works closely with the Digestive Disease Institute (DDI) at Virginia Mason, where approximately 2,000 patients with IBD are followed by one of the most highly acclaimed gastroenterology divisions in the Pacific Northwest, to provide clincal trials in IBD. The DDI maintains a robust IBD clinical research program with extensive experience in national clinical trials including past studies with abatacept and natalizumab, and ongoing studies with novel immunotherapies.
Virginia Mason tracks clinical outcomes and important metrics of quality care in all patients with IBD. BRI researchers have established an IBD biorespository to better understand the biomarkers associated with the progression of these diseases and to identify targets for new therapies.
Investigating the interactions between the intestinal mucosa and the regulatory mechanisms of the immune system, to better understand how these mechanisms break down in IBD. BRI scientists are also investigating how genes associated with autoimmunity alter the function of immune cells and lead to disease.